Of note, Erriquezet al. 100 utilized ovarian cancer PDX models and found an overexpression of topoisomerase II alpha (TOP2A) in cells from xenograft after the treatment of pegylated liposomal doxorubicin (PLD), suggesting that TOP2A may be involved in the pathogenesis of ovarian cancer response to PLD. The gene discussed is TOP2A; the disease is ovarian carcinoma.